Physician profile
Iguelle Bernard
NPI 1467183517
$7,389.06
in general payments reported to CMS, 2019-2025
17 companies · $3,051 in 2025
The $3,051 reported for 2025 was more than what 96% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $171 · 2023: $1,610 · 2024: $2,557 · 2025: $3,051.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,218.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,218.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $1,425.08 | 2023-2025 | Qelbree, Qelbree |
| Teva Pharmaceuticals USA, INC. | $1,075.77 | 2022-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Abbvie INC. | $980.95 | 2023-2025 | |
| Neurocrine Biosciences, INC. | $782.30 | 2023-2025 | Ingrezza |
| Otsuka America Pharmaceutical, INC. | $674.12 | 2023-2025 | Abilify Maintena, Rexulti, Abilify Asimtufii |
| Alkermes, INC. | $490.51 | 2022-2025 | Aristada, Lybalvi, Vivitrol |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $485.59 | 2022-2025 | Caplyta |
| Janssen Pharmaceuticals, INC | $352.34 | 2023-2025 | Invega Sustenna, Invega Trinza, Spravato |
| Lundbeck LLC | $298.51 | 2022-2025 | Rexulti |
| E.R. Squibb & Sons, L.L.C. | $226.27 | 2025 | Cobenfy |
| Collegium Pharmaceutical, INC. | $183.11 | 2025 | Jornay Pm |
| Ironshore Pharmaceuticals INC. | $111.15 | 2023-2024 | Jornay Pm |
| Vanda Pharmaceuticals INC. | $93.55 | 2025 | Fanapt, Hetlioz |
| Axsome Therapeutics, INC. | $79.08 | 2025 | Auvelity, Sunosi |
| Corium, LLC | $68.19 | 2022-2025 | Azstarys |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $48.76 | 2023-2025 | Trintellix |
| Indivior INC. | $13.78 | 2023 | Perseris |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Iguelle Bernard listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.